Zimbabwe has rejected a significant American healthcare agreement valued at $367m (272 million pounds) spanning five years over Washington's demand for confidential information.
This rejection was revealed after a official document from December was leaked, which showed Head of State Emmerson Mnangagwa deemed the agreement was "unbalanced".
An official spokesman later clarified that the US was seeking health data for research and profit but refused to share the resulting advantages from future treatments.
"We are forced to start the challenging and unfortunate task of ending our health assistance in Zimbabwe," remarked US ambassador to Zimbabwe Pamela Tremont publicly.
Her embassy said the US had donated more than $1.9bn for health programmes to Zimbabwe over the last twenty years.
A physicians' group in Zimbabwe has called for continued talks to find a deal agreeable to all parties so the nation's critical HIV treatment initiative can be sustained.
Broader Background
Zimbabwe's decision comes after a similar situation in Kenya, where a high court blocked a related deal with the US after concerns were filed about the security of citizens' health data.
Since resuming office last year, US President Donald Trump has drastically cut overseas assistance and shut down the US Agency for International Development (USAID).
USAID had overseen aid for the American government, but Trump argued its spending was "wasteful" and his administration was pursuing direct bilateral deals to enhance openness and accountability.
According to reports, Sixteen African countries have so far agreed to these new health pacts, representing more than $18.3bn in committed funds.
Details of the Rejected Deal
This assistance for Zimbabwe would have gone towards "tackling HIV/Aids, TB, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"It is our view this collaboration could have provided extraordinary advantages for the people of Zimbabwe, particularly the 1.2 million currently receiving antiretroviral therapy through American-funded programmes," Tremont said.
However, government spokesperson Nick Mangwana argued the arrangement was "unfair".
"Our nation was requested to provide its genetic material and health information indefinitely, with no equivalent guarantee of access to any medical innovations – like new medicines or tests – that could result from that shared data," his statement read.
"Put simply, our nation would supply the raw materials for scientific discovery without any certainty that the end products would be available to our population if a future disease outbreak emerge."
Sovereignty and Global Health
He also noted that the US's withdrawal from the global health body and its push of bilateral deals were upending systems previously established via the global health agency.
Mangwana gave as an example its Pandemic Benefit-Sharing system created to manage future pandemics.
"This system is intended to guarantee that when a country contributes its information, the benefits – including vaccines and treatments – are shared equitably, not commercialised exclusively by those with the resources to create them."
These objections over the US deal "should not be misconstrued as anti-American sentiment," Mangwana stressed.
"We welcome ongoing discussions with our American counterparts on how subsequent co-operation might be structured in a way that honours the sovereignty and interests of both nations."
Medical Community Reaction
The Zimbabwe College of Public Health Physicians (ZCPHP) said it understood the official position, but recommended that talks should continue given that a large portion of the nation's HIV programmes relied on external financing.
"Where specific concerns arise, including those involving data governance or implementation frameworks, these can often be resolved through technical clarification and mutually agreed protections," the group added.
The halted deal underscores the ongoing challenges between receiving crucial international aid and safeguarding a country's data in an increasingly data-driven world.